2022–2023 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates
CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies.
Infection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies.
Combined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both.
This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P3M |
| bureauCode |
[
"009:20"
]
|
| contactPoint |
{
"fn": "CDC-INFO",
"@type": "vcard:Contact",
"hasEmail": "mailto:cdcinfo@cdc.gov"
}
|
| description | CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies. Combined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022 |
| distribution |
[
{
"@type": "dcat:Distribution",
"mediaType": "text/csv",
"downloadURL": "https://data.cdc.gov/api/views/ar8q-3jhn/rows.csv?accessType=DOWNLOAD"
},
{
"@type": "dcat:Distribution",
"mediaType": "application/json",
"downloadURL": "https://data.cdc.gov/api/views/ar8q-3jhn/rows.json?accessType=DOWNLOAD"
},
{
"@type": "dcat:Distribution",
"mediaType": "application/rdf+xml",
"downloadURL": "https://data.cdc.gov/api/views/ar8q-3jhn/rows.rdf?accessType=DOWNLOAD"
},
{
"@type": "dcat:Distribution",
"mediaType": "application/xml",
"downloadURL": "https://data.cdc.gov/api/views/ar8q-3jhn/rows.xml?accessType=DOWNLOAD"
}
]
|
| identifier | https://data.cdc.gov/api/views/ar8q-3jhn |
| issued | 2022-11-04 |
| keyword |
[
"coronavirus",
"covid",
"covid-19",
"covid19",
"laboratory",
"prevalence",
"sars-cov",
"seroprevalence",
"serosurveys"
]
|
| landingPage | https://data.cdc.gov/d/ar8q-3jhn |
| license | https://www.usa.gov/government-works |
| modified | 2025-02-23 |
| programCode |
[
"009:020"
]
|
| publisher |
{
"name": "Centers for Disease Control and Prevention",
"@type": "org:Organization"
}
|
| spatial | US |
| temporal | 2022-01-01/2022-03-31 |
| theme |
[
"Laboratory Surveillance"
]
|
| title | 2022–2023 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates |
